Barclays PLC Acquires 5,229 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)

Barclays PLC boosted its position in MoonLake Immunotherapeutics (NASDAQ:MLTX) by 1,269.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,641 shares of the company’s stock after buying an additional 5,229 shares during the period. Barclays PLC’s holdings in MoonLake Immunotherapeutics were worth $283,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in MLTX. TD Asset Management Inc increased its position in MoonLake Immunotherapeutics by 2.5% in the 2nd quarter. TD Asset Management Inc now owns 209,234 shares of the company’s stock valued at $9,200,000 after buying an additional 5,140 shares in the last quarter. Victory Capital Management Inc. increased its position in MoonLake Immunotherapeutics by 16.0% in the 2nd quarter. Victory Capital Management Inc. now owns 174,682 shares of the company’s stock valued at $7,681,000 after buying an additional 24,037 shares in the last quarter. Federated Hermes Inc. increased its position in MoonLake Immunotherapeutics by 2.6% in the 2nd quarter. Federated Hermes Inc. now owns 1,128,428 shares of the company’s stock valued at $49,617,000 after buying an additional 28,672 shares in the last quarter. Avoro Capital Advisors LLC increased its position in MoonLake Immunotherapeutics by 7.4% in the 2nd quarter. Avoro Capital Advisors LLC now owns 2,770,000 shares of the company’s stock valued at $121,797,000 after buying an additional 190,000 shares in the last quarter. Finally, Logos Global Management LP bought a new stake in MoonLake Immunotherapeutics in the 2nd quarter valued at about $32,978,000. 93.85% of the stock is owned by institutional investors.

MoonLake Immunotherapeutics Stock Down 0.2 %

Shares of NASDAQ MLTX opened at $53.45 on Monday. MoonLake Immunotherapeutics has a twelve month low of $37.55 and a twelve month high of $64.98. The stock’s 50 day moving average price is $52.01 and its 200-day moving average price is $48.57. The company has a market capitalization of $3.42 billion, a PE ratio of -41.43 and a beta of 1.31.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.12). During the same quarter last year, the firm posted ($0.18) earnings per share. As a group, research analysts expect that MoonLake Immunotherapeutics will post -1.75 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have commented on MLTX. Needham & Company LLC reissued a “buy” rating and set a $62.00 price objective on shares of MoonLake Immunotherapeutics in a report on Thursday, September 12th. HC Wainwright reissued a “buy” rating and set a $100.00 price objective on shares of MoonLake Immunotherapeutics in a report on Thursday, November 14th. Cantor Fitzgerald reissued an “overweight” rating on shares of MoonLake Immunotherapeutics in a report on Monday, September 23rd. Finally, Wedbush restated an “outperform” rating and issued a $73.00 target price (down previously from $92.00) on shares of MoonLake Immunotherapeutics in a research note on Tuesday, November 5th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, MoonLake Immunotherapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $81.43.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.